Orchestra BioMed (OBIO) to Release Quarterly Earnings on Wednesday

Orchestra BioMed (NASDAQ:OBIO) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Orchestra BioMed to post earnings of ($0.38) per share and revenue of $0.9310 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.64. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The business had revenue of $30.92 million during the quarter, compared to analyst estimates of $0.93 million. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Orchestra BioMed Price Performance

Shares of NASDAQ:OBIO opened at $4.26 on Monday. The stock has a market capitalization of $249.30 million, a P/E ratio of -3.77 and a beta of 0.56. The stock’s 50-day moving average price is $4.20 and its 200-day moving average price is $3.99. The company has a current ratio of 6.45, a quick ratio of 6.43 and a debt-to-equity ratio of 0.27. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OBIO. Barclays increased their target price on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. TD Cowen began coverage on Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating for the company. Finally, Wall Street Zen raised Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.25.

Insider Buying and Selling at Orchestra BioMed

In other news, insider David P. Hochman bought 10,000 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was bought at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the acquisition, the insider owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after buying an additional 324,558 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Orchestra BioMed during the third quarter valued at approximately $3,386,000. Pathstone Holdings LLC bought a new position in shares of Orchestra BioMed during the third quarter valued at approximately $2,495,000. Geode Capital Management LLC raised its holdings in shares of Orchestra BioMed by 22.4% during the fourth quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock valued at $1,965,000 after acquiring an additional 86,564 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Orchestra BioMed by 46.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock worth $1,095,000 after acquiring an additional 83,349 shares during the period. Hedge funds and other institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.